Measurement-Based Care Vs. Standard Care for Major Depressive Disorder

Major Depressive Disorder Clinical Trial

— MBC  

Official title:

A Randomized Controlled Trial of Measurement-Based Care Vs. Standard Care for Major Depressive Disorder in Pakistan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05431374
• Other study ID #: MBC-Depression
• Secondary ID: Depression
• Status: Completed
• Phase: Phase 3
• Start date: September 1, 2022
• Est. completion date: January 30, 2024

Study information

• Verified date: August 2023
• Source: Pakistan Institute of Living and Learning
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, indicated as one of the two most disabling mental disorders by the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 (Vos et al., 2020). Despite several effective pharmacological and psychosocial interventions available globally, only about one-third of depressed patients achieve remission (Xiao et al., 2021). There is a need to establish scalable clinical management practices which utilize biopsychosocial assessments, formulate a differential diagnosis, and provide evidence-based treatments for patients with MDD (Hong et al., 2021). While significant evidence for effectiveness of Measurement Based Care (MBC) is found in clinical settings from high and middle-income countries, assessments of MBC compared with usual care for the treatment of MDD are yet to be completed in low-resource settings like LMICs. The aim of this trial is to determine the efficacy and safety of MBC in patients with MDD in comparison with standard care in Pakistan. In order to reduce the variance found in treatment-as-usual and isolate the impact of MBC, standard care for this trial will limit medication choices to either paroxetine or mirtazapine.

Description:

Hypothesis: The rates of response and remission, and time to response and remission would be significantly shorter in the MBC group, without greater dropout rates and side effect burden, compared with the standard treatment group.

Study design and setting This will be a multi-centre, with assessors blind to protocol and treatment group, parallel arm, randomized controlled trial (RCT). The study is a direct replication of a study conducted by Gou et al. (2015) in China.

Participants Participants will be recruited from psychiatric units of teaching and non-teaching hospitals in 6 centres: Karachi (population 23 million), Lahore (population 10 million), Rawalpindi (population 3 million), Hyderabad (population 2 million) and Quetta (population 1 million) and Multan (1.8 million).

Sample size The sample size of 120 participants for this exploratory trial is based on the study conducted by Guo et al.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: January 30, 2024
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Adult outpatients age 18-65 of age

2. Diagnosis of nonpsychotic MDD established by treating psychiatrists and confirmed by a checklist based on DSM-5 criteria at study entry

3. Currently depressed with a score >17 on the 17-item Hamilton Depression Rating (HDRS-17)

4. Able to communicate effectively and give written informed consent

5. Resident of the trial catchment area.

Exclusion Criteria:

1. Lifetime history of drug or alcohol dependence; 2. Diagnosis of bipolar, psychotic, obsessive-compulsive, or eating disorders confirmed with DSM-5 criteria 3. History of a lack of response or intolerance to either of the two protocol antidepressants (paroxetine and mirtazapine) 4. Currently pregnancy or breastfeeding; 5. Suicide attempts in the current depressive episode; 6. Any major medical condition contraindicating the use of the protocol antidepressants.

-

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Measurement Based Care (MBC)
Patients in both groups will receive either open-label paroxetine (20-50mg/day) or open-label mirtazapine (15-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges. patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient.
• Control/Standard-care
Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.

Locations

Country	Name	City	State
Pakistan	Civil Hospital	Hyderabad
Pakistan	Civil Hospital	Karachi	Sindh
Pakistan	Services Hospital	Lahore	Punjab
Pakistan	Nishtar Hospital	Multan	Punjab
Pakistan	Bolan Medical Complex	Quetta	Balochistan
Pakistan	Benazir Bhutto Hospital	Rawalpindi	Punjab

Sponsors (2)

Lead Sponsor	Collaborator
Pakistan Institute of Living and Learning	University of Toronto

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Depression Rating (HDRS-17) - Response	is a 17-item instrument that was designed to measure frequency and intensity of depressive symptoms in individuals with major depressive disorder. Ratings are made using either a five- or a three-point scale, yielding total scores from zero to 61. Response will be defined as a decrease of 50% from the baseline HAM-D score.	Change in scores from baseline to 3-month follow up (end of intervention)
Primary	Hamilton Depression Rating (HDRS-17) - Remission	is a 17-item instrument that was designed to measure frequency and intensity of depressive symptoms in individuals with major depressive disorder. Ratings are made using either a five- or a three-point scale, yielding total scores from zero to 61. Remission as a HAM-D score<7	Change in scores from baseline to 3-month follow up (end of intervention) and 6-month follow up
Secondary	Frequency, Intensity, and Burden of Side Effects Rating scale	is a self-report instrument assessing three domains of medication side effects within the past week: frequency, intensity, and burden (the degree to which side effects over the past week interfered with day-to-day functions). Each domain is rated on a 7-point (0-6) scale (frequency, ranging from "no side effects" to "present all of the time"; intensity, ranging from "no side effects" to "intolerable"; and burden, ranging from "no impairment" to "unable to function"). A low score (0-2) indicates that current treatment may continue; an intermediate score (3 or 4) suggests that side effects require attention, a high score (5 or 6) means that the current treatment is unacceptable and a decrease in dosage or a medication switch is needed. Will be administered in the MBC group only	Change in scores at each week for up to 12 weeks.
Secondary	Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)	A 16-item scale to measure the severity of depressive symptoms within the past week. On the QIDS-SR, higher scores indicate more severe depressive symptoms. Will be administered in the MBC group only	Change in scores at each week for up to 12 weeks.
Secondary	Hamilton Depression Rating (HDRS-17) - Severity	is a 17-item instrument that was designed to measure frequency and intensity of depressive symptoms in individuals with major depressive disorder. Ratings are made using either a five- or a three-point scale, yielding total scores from zero to 61. Higher scores indicate higher severity.	Change in scores from baseline to 3-month follow up (end of intervention)and 6-month follow up
Secondary	Additional Side-effect Checklist	This additional side-effect checklist include some common side effects of ant-depressant medications,	Change in score from baseline to 3-month follow up and 6-month follow up